HIV Prevention: A Game-Changer in the Fight Against the Epidemic
Lima, Peru – The 5th HIV Research for Prevention Conference (HIVR4P 2024) has brought together experts in the field of HIV prevention research, and the message is clear: we need to focus on prevention, not just cure. The harsh reality is that we don’t know when or if there will be a cure for HIV, and the virus is getting smarter, mutating quickly, making it challenging to develop a long-awaited cure.
However, there is a silver lining. The conference has highlighted promising developments in HIV prevention, particularly the twice-yearly injectable PrEP drug, lenacapavir. In the PURPOSE 1 and PURPOSE 2 trials, lenacapavir demonstrated remarkable efficacy in preventing HIV acquisition, with a 100% reduction in HIV acquisitions among cisgender women in Africa and a 96% reduction across multiple countries.
Lenacapavir is a game-changer in HIV prevention, offering a practical and stigma-reducing option, especially for women who have historically faced barriers to adherence to traditional PrEP. As Beatriz Grinsztejn, President of the International AIDS Society (IAS), noted, these findings could transform HIV prevention for all genders.
Another long-acting tool gaining attention is the dapivirine vaginal ring, already approved in 11 African countries. Women who participated in its trial praised the ring, saying it’s “hot” and enjoyable, which is crucial, as researchers have emphasized that incorporating pleasure into HIV prevention methods can boost adherence. A new data from South Africa suggests that a three-month version of the ring could significantly improve both convenience and cost-effectiveness, making it especially essential for women in rural or under-resourced areas.
The key takeaway from the HIVR4P 2024 is that people must not die while waiting for a cure when powerful preventive tools already exist. It’s time for all, especially those in vulnerable communities, to take up these cool prevention methods as they become available.
